Nanogam (Human Normal Immunoglobulin)

Human normal immunoglobulin provides a broad spectrum of pooled IgG antibodies that bind to pathogens, neutralize toxins, and activate complement. By supplementing the patient’s own antibody pool, it restores immune surveillance and enhances the body’s ability to fight bacterial, viral, and toxin‑mediated infections.

The dose of Nanogam is individualized by the prescribing clinician based on the patient’s body weight, baseline IgG level, severity of immunodeficiency, and clinical response. Dosing regimens are adjusted to achieve target IgG concentrations while minimizing adverse effects.

Safety data for Nanogam in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible.

To order Nanogam, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Nanogam is a pooled human IgG solution manufactured in the EU and meets stringent quality standards. Compared with other IVIGs, it offers comparable efficacy in infection prevention, but specific formulation differences such as stabilizers, IgA content, and osmolarity may influence tolerability and infusion rates.

Nanogam must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and allowed to reach room temperature if required by the infusion protocol.

Nanogam is given as an intravenous infusion. The infusion rate is usually started slowly and increased as tolerated, following the prescribing information. Administration is performed by qualified healthcare professionals in a setting equipped to manage potential infusion reactions.

Serious risks include anaphylaxis, hemolytic anemia, thromboembolic events, acute renal failure, and aseptic meningitis. Patients should be closely monitored during and after infusion for signs of these reactions, and immediate medical intervention should be available.

Nanogam is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as well as in patients who have experienced a previous severe hypersensitivity reaction to immunoglobulin products. Caution is also advised for patients with uncontrolled renal or cardiovascular disease.